ALQA ~ Big Upside Short term (Large Shareholder of ALQA is CEO of 34BB Teva).. Members do not miss out on ALQA.. We are now calling ALQA the Top Best FDA Approved Biotech Play in the Otcmarkets.. We feel ALQA will be on Fire next week so take advantage of it now before Thanksgiving or on Friday (but its only a half day trading on Friday so it might be hard to get shares)... ALQA Huge news and very Bullish ~ One of the largest shareholders and Institutions in ALQA is Frost Gamma ... Frost Gamma is the investment arm of Dr. Phillip Frost, the current Chairman of Teva Pharmaceuticals (a $34BB company). Dr. Frost amassed his multi-billion dollar fortune in the pharmaceutical industry and his Frost Gamma Trust invests in numerous companies in the healthcare space... ALQA ~ We are hearing Big things are in the pipeline for ALQA and we feel now is the time to take advantage of ALQA being quite prior to Thanksgiving. ALQA should breakout next week but we feel ALQA will be hard to time so Don't Miss out on ALQA while its cheap and quite. A lot of our Members chased our other play and it ended up running over 2,100% ... read full: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=81709227 **********************************************************
recent news/filings
Nov 19, 2012 Alliqua to Explore Business Development Efforts for Hydrogel Transdermal Delivery Platform in the Cosmeceutical Industry Alliqua announced the Company's exploration of business development efforts for its proprietary transdermal delivery platform in the cosmeceutical industry. According to market research data from the Freedonia Group, the cosmeceutical market reached $6.4 billion in 2010 and is projected to grow to $8.5 billion by 2015, largely fueled by consumers searching to stave off the physical signs of aging. read full: http://finance.yahoo.com/news/alliqua-explore-business-development-efforts-123000680.html **********************************************************
Nov 15, 2012 Alliqua Appoints Dr. Joseph Laudano as Vice President of Medical Affairs to Support the Market Expansion of Alliqua's SilverSeal Products and Future Clinical Development appointment of Joseph Laudano, Pharm.D. to the newly created position of Vice President, Medical Affairs to support the market expansion of Alliqua's SilverSeal® products as well as other future clinical developments. Dr. Laudano will lead the development of a medical affairs team at Alliqua as the company now begins to step up the marketing efforts for our proprietary 510K FDA approved SilverSeal® hydrogels for wound care. He will also play a key role in the planning and clinical development of our platform for transdermal drug delivery Commenting on the appointment, James Sapirstein, CEO of Alliqua stated, "We are very pleased to have an industry veteran of such high caliber join our team here at Alliqua. One of my primary near term goals as CEO of this company is to put the right people in place that can deliver on the rich potential of our proprietary technology as well as our future strategic plans. Joe has extensive experience in some key therapeutic areas such as dermatology and infectious diseases, which I believe align nicely with Alliqua's future needs as we build this organization." read full: http://finance.yahoo.com/news/alliqua-appoints-dr-joseph-laudano-123000587.html **********************************************************
Nov 14, 2012 ALLIQUA, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers read full: http://biz.yahoo.com/e/121114/alqa8-k.html **********************************************************
Nov 13, 2012 Alliqua Launches New Sales Initiative for SilverSeal(R) Hydrogels at Desert Foot 2012 Conference in Arizona on November 14-16 Alliqua's manufacturing facility has a current production capacity to support approximately $80 million in sales of hydrogels on an annual basis with room for further expansion. With the overall market for hydrogels expected to exceed $1 billion in the next three years according to MarketsandMarkets, management intends to aggressively build its own proprietary line of hydrogels and provide private label products to other companies to rapidly expand its plant utilization rates. Commenting on the marketing efforts, Mr. James Sapirstein, CEO of Alliqua, commented, "As we look to build Alliqua for the future, it is important to focus on two important facets of the company. The launch of this sales effort for our hydrogels is really the low hanging fruit for us in that we have a superior product and the production capability to generate substantial near term revenue without the need for large capital expenditures. If we build that business as we expect we can, we will be able to utilize the cash generated from those operations to invest in the other aspect of our business which is using our platform for drug delivery. We believe that success in drug delivery will enable us to tap into vast pharmaceutical markets and build our company into a truly world class organization for the benefit of our shareholders." read full: http://finance.yahoo.com/news/alliqua-launches-sales-initiative-silverseal-123000151.html **********************************************************
chart
golden cross coming!!
ticker: $ALQA isin code: US0196211017 company name: Alliqua, Inc. company website: http://www.alliqua.com - http://alliqua1.nextmp.net
incorporated In: FL, USA sos filings: http://www.sunbiz.org/scripts/cordet.exe?action=DETFIL&inq_doc_number=P97000090722&inq_came_from=NAMFWD&cor_web_names_seq_number=0002&names_name_ind=&names_cor_number=&names_name_seq=&names_name_ind=&names_comp_name=ALLIQUA&names_filing_type=
Business Description: Alliqua, Inc., a biomedical products company, through its subsidiaries, focuses on the development and manufacture of proprietary technologies in the fields of drug delivery, advanced wound care, and liver health preservation. The company intends to develop, manufacture, and market active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform. It also manufactures custom hydrogels that are used for transdermal drug delivery, wound care, medical diagnostics, and cosmetics. In addition, Alliqua offers HepaMate, an extracorporeal cell-based bioartificial liver system to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the severe forms of liver failure.
$ALQA Products and Services: http://alliqua1.nextmp.net/products-and-services.html
Market Data 
Markets 
AI
